These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30972278)

  • 21. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor.
    Zhi J; Yi J; Hou X; Wang W; Yang W; Hu L; Huang J; Guo S; Ruan X; Gao M; Zheng X
    Am J Cancer Res; 2022; 12(1):247-264. PubMed ID: 35141016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition.
    Yangchun M; WenYu Y; Liang Z; LiPeng L; JingWei W; WeiYa L; Shan D; Ying M; RunLing W
    Mol Divers; 2022 Jun; 26(3):1567-1580. PubMed ID: 34338914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.
    Lu H; Liu C; Huynh H; Le TBU; LaMarche MJ; Mohseni M; Engelman JA; Hammerman PS; Caponigro G; Hao HX
    Oncotarget; 2020 Jan; 11(3):265-281. PubMed ID: 32076487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATPR induces acute promyelocytic leukemia cells differentiation and growth arrest by blockade of SHP2/Rho/ROCK1 pathway.
    Li L; Xu X; Du Y; Zhang M; Feng Y; Qian X; Li S; Du T; Peng X; Chen F
    Toxicol Appl Pharmacol; 2020 Jul; 399():115053. PubMed ID: 32417439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective inhibition of leukemia-associated SHP2
    Sun X; Ren Y; Gunawan S; Teng P; Chen Z; Lawrence HR; Cai J; Lawrence NJ; Wu J
    Leukemia; 2018 May; 32(5):1246-1249. PubMed ID: 29568093
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer.
    Wang P; Han Y; Pan W; Du J; Zuo D; Ba Y; Zhang H
    MedComm (2020); 2024 Apr; 5(4):e527. PubMed ID: 38576457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.
    Sun B; Jensen NR; Chung D; Yang M; LaRue AC; Cheung HW; Wang Q
    Am J Cancer Res; 2019; 9(1):145-159. PubMed ID: 30755818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
    Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
    J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
    BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
    Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 35. Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment.
    Xiao P; Guo Y; Zhang H; Zhang X; Cheng H; Cao Q; Ke Y
    Oncogene; 2018 Sep; 37(37):5088-5100. PubMed ID: 29795405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
    Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
    Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
    Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
    Jin WY; Ma Y; Li WY; Li HL; Wang RL
    Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NanoSHP099-Targeted SHP2 Inhibition Boosts Ly6C
    Ying K; Xin W; Xu Y; Lv D; Zhu H; Li Y; Xu W; Yan C; Li Y; Cheng H; Chen E; Ma G; Zhang X; Ke Y
    Adv Sci (Weinh); 2024 Apr; 11(13):e2308166. PubMed ID: 38247197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
    Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
    ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.